Market World Next Generation Cancer Diagnostics Market | Page 3

The prognostic diagnostics segment is anticipated to witness the fastest growth in the coming years as a
consequence of higher adoption of prognosis which plays important role in designing oncology therapies and
protocols for chemotherapy, radiation-based treatment, and gene therapy.
Regional Insights
The next generation cancer diagnostics market is dominated by North America with approximately 40% market
share. Favorable government initiatives such as launch of “80% by 2018” program for detection of colon cancer
is anticipated to propel progress in the coming years.
In this program, almost 170 groups including medical professional societies, health departments, government
health departments, and cancer coalitions are functioning to accomplish the mutual goal of attaining 80%
screening for oncology diseases by 2018 and are working forward to eliminate the oncology disorders.
Asia Pacific is anticipated to be the fastest developing region. Factors such as economic augmentation, higher
investments, and greater untapped market are accountable for the fastest growth of resign in diagnosis sector.
Competitive Insights
Major entities functioning in the market include Novartis AG, Myriad Genetics Inc., Illumina Inc., Almac Group,
Sysmex Corporation, F. Hoffmann-La Roche Ltd, Agilent Technologies, Genomic Health, Almac Group,
Koninklijke Philips N.V, and Cepheid.
Market players by offering clinical analysis amenities are implementing geographic expansion strategies.
Furthermore, reimbursement coverage plays an important factor to increase the patient convenience to the
precision drug. For example, in October 2015, U.S., Medicare started the reimbursement procedure for a
prostate tumor type known as Oncotype DX.
Market Segment:
Technology Outlook (Revenue, USD Million, 2013 - 2024)
• Next Generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays